If you didn’t tune in for the riveting Senate hearing over the nomination of the new NIH Director Monica Bertagnolli, you might have missed the back-and-forth between Senators Sanders and Cassidy over whether the NIH should exercise march-in rights as to overpriced pharmaceuticals that were developed with NIH funding. Sanders had previously held up the nomination hearing
Excellent article Stuart. I've wondered for years why there isn't a mechanism for recapturing NIH (tax dollars) investments in basic research when it is "commercialized" so those funds can be ploughing back into the discovery stages of the pipeline. Of course this would be unpopular with big pharma and lobbied against hard.
Excellent article Stuart. I've wondered for years why there isn't a mechanism for recapturing NIH (tax dollars) investments in basic research when it is "commercialized" so those funds can be ploughing back into the discovery stages of the pipeline. Of course this would be unpopular with big pharma and lobbied against hard.